Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
MarketBeat
Adicet Bio (NASDAQ:ACET) reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including patients with lupus nephritis.
The company said that, among evaluable lupus nephritis patients, 50%
NASDAQ:ACET